Cancer Clinical Trials
This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Melenoma - Advanced
Trial Name: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High dose Interferon a-2b for Resected High-Risk Melanoma.
Protocol ID: ECOG - 1609
Women must not be pregnant or breast-feeding due to the unknown effects of ipilimumab and HDI on conception and the fetus.
Enrollment: • About 1000 people will take part in this study at several medical centers.
Taking part in this study may or may not make your health better. While doctors hope that ipilimumab will be more useful against cancer compared to the usual treatment, there is no proof of this yet. We do know that the information from the study will help doctors learn more about ipilimumab and interferon Alfa-2b as a treatment for caner. This information could help future cancer patients.
These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Aspirus Regional Cancer Center Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353, or Langlade Cancer Center Research Nurse Debra Witman @ 715-623-9587.
Created: Jun 3, 2011
Updated: May 21, 2014